View in EDS

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Saved in:
Bibliographic Details
Title: Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Authors: Dummer R; aDepartment of Dermatology, Skin Cancer Unit, University Hospital Zurich, Zurich, Switzerland., Sandhu S; bSir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Australia., Miller WH Jr; cLady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Canada., Butler MO; dPrincess Margaret Cancer Centre, University Health Network, Departments of Medicine and Immunology, University of Toronto, Toronto, Canada., Taylor MH; eEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Heinzerling L; fDepartment of Dermatology and Allergy, University Hospital, Ludwig Maximilian University, Munich, Germany., Blank CU; gDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Couselo EM; hDepartment of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Burris HA 3rd; iSarah Cannon Research Institute, Nashville, TN, USA., Postow MA; jDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA., Chmielowski B; kJonsson Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Middleton MR; lNIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, UK., Berking C; mDepartment of Dermatology, Uniklinikum Erlangen, CCC Erlangen - EMN, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Hassel JC; nHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany., Gesierich AH; oDepartment of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany., Mauch C; pDepartment of Dermatology and Venereology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Kleha JF; qPfizer, New York, NY, USA., Polli A; rPfizer, Milan, Italy., Harney AS; sPfizer Boulder Research Unit, Boulder, CO, USA., di Pietro A; rPfizer, Milan, Italy., Ascierto PA; tMelanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
Source: Future oncology (London, England) [Future Oncol] 2026 Apr; Vol. 22 (9), pp. 995-1013. Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41914670
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dummer+R%22">Dummer R</searchLink>; aDepartment of Dermatology, Skin Cancer Unit, University Hospital Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sandhu+S%22">Sandhu S</searchLink>; bSir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Miller+WH+Jr%22">Miller WH Jr</searchLink>; cLady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Departments of Medicine and Oncology, McGill University, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Butler+MO%22">Butler MO</searchLink>; dPrincess Margaret Cancer Centre, University Health Network, Departments of Medicine and Immunology, University of Toronto, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Taylor+MH%22">Taylor MH</searchLink>; eEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.<br /><searchLink fieldCode="AU" term="%22Heinzerling+L%22">Heinzerling L</searchLink>; fDepartment of Dermatology and Allergy, University Hospital, Ludwig Maximilian University, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Blank+CU%22">Blank CU</searchLink>; gDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Couselo+EM%22">Couselo EM</searchLink>; hDepartment of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; iSarah Cannon Research Institute, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Postow+MA%22">Postow MA</searchLink>; jDepartment of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Chmielowski+B%22">Chmielowski B</searchLink>; kJonsson Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Middleton+MR%22">Middleton MR</searchLink>; lNIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22Berking+C%22">Berking C</searchLink>; mDepartment of Dermatology, Uniklinikum Erlangen, CCC Erlangen - EMN, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.<br /><searchLink fieldCode="AU" term="%22Hassel+JC%22">Hassel JC</searchLink>; nHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Gesierich+AH%22">Gesierich AH</searchLink>; oDepartment of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Mauch+C%22">Mauch C</searchLink>; pDepartment of Dermatology and Venereology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Kleha+JF%22">Kleha JF</searchLink>; qPfizer, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Polli+A%22">Polli A</searchLink>; rPfizer, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Harney+AS%22">Harney AS</searchLink>; sPfizer Boulder Research Unit, Boulder, CO, USA.<br /><searchLink fieldCode="AU" term="%22di+Pietro+A%22">di Pietro A</searchLink>; rPfizer, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; tMelanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2026 Apr; Vol. 22 (9), pp. 995-1013. <i>Date of Electronic Publication: </i>2026 Mar 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41914670
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2026.2643481
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 995
    Titles:
      – TitleFull: Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dummer R
      – PersonEntity:
          Name:
            NameFull: Sandhu S
      – PersonEntity:
          Name:
            NameFull: Miller WH Jr
      – PersonEntity:
          Name:
            NameFull: Butler MO
      – PersonEntity:
          Name:
            NameFull: Taylor MH
      – PersonEntity:
          Name:
            NameFull: Heinzerling L
      – PersonEntity:
          Name:
            NameFull: Blank CU
      – PersonEntity:
          Name:
            NameFull: Couselo EM
      – PersonEntity:
          Name:
            NameFull: Burris HA 3rd
      – PersonEntity:
          Name:
            NameFull: Postow MA
      – PersonEntity:
          Name:
            NameFull: Chmielowski B
      – PersonEntity:
          Name:
            NameFull: Middleton MR
      – PersonEntity:
          Name:
            NameFull: Berking C
      – PersonEntity:
          Name:
            NameFull: Hassel JC
      – PersonEntity:
          Name:
            NameFull: Gesierich AH
      – PersonEntity:
          Name:
            NameFull: Mauch C
      – PersonEntity:
          Name:
            NameFull: Kleha JF
      – PersonEntity:
          Name:
            NameFull: Polli A
      – PersonEntity:
          Name:
            NameFull: Harney AS
      – PersonEntity:
          Name:
            NameFull: di Pietro A
      – PersonEntity:
          Name:
            NameFull: Ascierto PA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1